Aligos Therapeutics, Inc.
ALGS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001799448
No open-market purchases or sales by Aligos Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.2M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
13F holders, Q4 2022
Institutional positions in Aligos Therapeutics, Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 39
- −13 vs. Q3 2022
- Shares held
- 26.5M
- −1.12M (−4.1%) vs. Q3 2022
- Total value
- $25.3M
- −$5.13M (−16.9%) vs. Q3 2022
- New holders
- 1
- 11 more added
- Sold out
- 14
- 14 more reduced
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ALGS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 31 | $13.2M |
| Q1 2026 | 35 | $20.6M |
| Q4 2025 | 41 | $26.2M |
| Q3 2025 | 33 | $26.0M |
| Q2 2025 | 37 | $19.5M |
| Q1 2025 | 35 | $27.1M |
| Q4 2024 | 34 | $64.5M |
| Q3 2024 | 27 | $14.7M |
| Q2 2024 | 49 | $16.6M |
| Q1 2024 | 49 | $45.3M |
| Q4 2023 | 40 | $30.1M |
| Q3 2023 | 36 | $19.2M |
| Q2 2023 | 41 | $25.5M |
| Q1 2023 | 46 | $23.9M |
| Q4 2022 | 39 | $25.3M |
| Q3 2022 | 52 | $30.4M |
| Q2 2022 | 60 | $36.0M |
| Q1 2022 | 76 | $68.4M |
| Q4 2021 | 71 | $390.4M |
| Q3 2021 | 68 | $483.9M |
| Q2 2021 | 58 | $550.5M |
| Q1 2021 | 52 | $612.4M |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding Aligos Therapeutics, Inc.; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 3,948,360 | $3.76M | 0.11% | 00.0% | Unchanged |
| Vivo Capital, LLC | 3,547,030 | $3.38M | 0.41% | 00.0% | Unchanged |
| Tang Capital Management LLC | 2,816,391 | $2.68M | 0.39% | +1,142,225+68.2% | Added |
| Versant Venture Management, LLC | 2,320,381 | $2.21M | 4.58% | 00.0% | Unchanged |
| HHLR Advisors, Ltd.SuperinvestorHHLR Advisors (Hillhouse) | 2,309,764 | $2.20M | 0.05% | −55,300−2.3% | Reduced |
| Baker Bros. Advisors LP | 2,076,400 | $1.98M | 0.01% | 00.0% | Unchanged |
| Newtyn Management, LLC | 1,500,000 | $1.43M | 0.29% | +500,000+50.0% | Added |
| Adage Capital Partners GP, L.L.C. | 1,473,278 | $1.40M | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 1,150,148 | $1.09M | 0.00% | +2,006+0.2% | Added |
| Vanguard Group Inc | 1,013,496 | $965.8K | 0.00% | −76,496−7.0% | Reduced |
| Point72 Asset Management, L.P. | 905,896 | $863.2K | 0.00% | −11,140−1.2% | Reduced |
| Pivotal bioVenture Partners Investment Advisor LLC | 743,215 | $708.3K | 0.31% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 532,260 | $507.0K | 0.00% | −198,338−27.1% | Reduced |
| Millennium Management LLC | 371,319 | $354.0K | 0.00% | +39,188+11.8% | Added |
| Acadian Asset Management LLC | 334,704 | $318.0K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 307,449 | $293.0K | 0.00% | −210,110−40.6% | Reduced |
| New York Life Investment Management LLC | 263,832 | $251.4K | 0.00% | +29,732+12.7% | Added |
| Geode Capital Management, LLC | 199,858 | $190.0K | 0.00% | +9,440+5.0% | Added |
| Bridgeway Capital Management, LLC | 112,000 | $106.7K | 0.00% | +33,000+41.8% | Added |
| Two Sigma Investments, LP | 90,418 | $86.2K | 0.00% | −34,008−27.3% | Reduced |
| Citadel Advisors LLC | 86,278 | $82.2K | 0.00% | +12,983+17.7% | Added |
| Two Sigma Advisers, LP | 82,500 | $78.6K | 0.00% | −35,000−29.8% | Reduced |
| Deutsche Bank AG | 71,290 | $67.9K | 0.00% | 00.0% | Unchanged |
| HRT Financial LP | 66,259 | $63.0K | 0.00% | −35,513−34.9% | Reduced |
| State Street Corp | 60,823 | $58.0K | 0.00% | 00.0% | Unchanged |
| Ergoteles LLC | 36,367 | $34.7K | 0.00% | −16,522−31.2% | Reduced |
| Northern Trust Corp | 32,604 | $31.1K | 0.00% | 00.0% | Unchanged |
| HarbourVest Partners LLC | 18,783 | $17.9K | 0.01% | 00.0% | Unchanged |
| Jane Street Group, LLC | 16,420 | $15.6K | 0.00% | +16,420 | New |
| Advisor Group Holdings, Inc. | 8,000 | $8.00K | 0.00% | 00.0% | Unchanged |
| Federated Hermes, Inc. | 3,180 | $3.03K | 0.00% | +1,163+57.7% | Added |
| Morgan Stanley | 2,353 | $2.24K | 0.00% | −7,929−77.1% | Reduced |
| JPMorgan Chase & Co | 677 | $1.00K | 0.00% | −3,125−82.2% | Reduced |
| FMR LLC | 1,012 | $964 | 0.00% | −1−0.1% | Reduced |
| Wells Fargo & Company | 173 | $165 | 0.00% | +4+2.4% | Added |
| Citigroup Inc | 85 | $81 | 0.00% | −478−84.9% | Reduced |
| Newbridge Financial Services Group, Inc. | 37 | $35 | 0.00% | 00.0% | Unchanged |
| Cubist Systematic Strategies, LLC | 3 | $3 | 0.00% | −23−88.5% | Reduced |
| Royal Bank of Canada | 18 | $0 | 0.00% | +5+38.5% | Added |
| Novo Holdings A/S | 0 | $0 | 0.00% | −1,950,000−100.0% | Sold out |
| Rockefeller Capital Management L.P. | 0 | $0 | 0.00% | −77,499−100.0% | Sold out |
| Oasis Management Co Ltd. | 0 | $0 | 0.00% | −45,797−100.0% | Sold out |
| Brinker Capital Investments, LLC | 0 | $0 | 0.00% | −37,981−100.0% | Sold out |
| D. E. Shaw & Co., Inc. | 0 | $0 | 0.00% | −31,568−100.0% | Sold out |
| Bailard, Inc. | 0 | $0 | 0.00% | −19,400−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −16,031−100.0% | Sold out |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −14,043−100.0% | Sold out |
| Balyasny Asset Management LLC | 0 | $0 | 0.00% | −11,999−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −10,513−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −8,062−100.0% | Sold out |
| Capital Advisors, Ltd. LLC | 0 | $0 | 0.00% | −667−100.0% | Sold out |
| Daiwa Securities Group Inc. | 0 | $0 | 0.00% | −115−100.0% | Sold out |
| China Universal Asset Management Co., Ltd. | 0 | $0 | 0.00% | −372−100.0% | Sold out |